Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 7/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29748830 | 1.00 | PTGS2 (0.55) | PTGS2BRD4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9656995 | 0.91 | PTGS2 (0.56) | PTGS2BRD4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9656728 | 0.91 | PTGS2 (0.53) | PTGS2BRD4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9657518 | 0.90 | PTGS2 (0.55) | PTGS2BRD4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9656825 | 0.89 | PTGS2 (0.54) | PTGS2BRD4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9656981 | 0.89 | PTGS2 (0.54) | PTGS2BRD4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9658252 | 0.89 | CXCL8 (0.48) | PTGS2CYP1A2CYP3A4MAPTALDH1A1 | |
| SCHEMBL9657068 | 0.88 | PTGS2 (0.53) | PTGS2BRD4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9658615 | 0.88 | MRGPRX1 (0.48) | PTGS2BRD4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9617920 | 0.88 | PTGS2 (0.53) | PTGS2BRD4CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1617816-B1 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2009-05-13 | — | — | EP | claimed |
| EP-0273369-B1 | NEW ALKANESULFONANILIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-04 | — | — | EP | claimed |
| US-4866091-A | ANTINFLAMMATORY AGENTS, ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-12 | — | — | US | claimed |
| JP-63190869-A | — | — | None | — | — | JP | disclosed |
| US-11717481-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-08-08 | — | — | US | disclosed |
| US-20220211626-A1 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-07-07 | — | — | US | disclosed |
| US-11253478-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-02-22 | — | — | US | disclosed |
| US-20210113580-A1 | NANOPARTICULATE MELOXICAM FORMULATIONS | BAUDAX BIO, INC. | 2021-04-22 | — | — | US | disclosed |
| EP-3434261-B1 | FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM | BAUDAX BIO INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10709713-B2 | Nanoparticulate meloxicam formulations | BAUDAX BIO, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200155564-A1 | Nanoparticulate Meloxicam Formulations | RECRO TECHNOLOGY LLC | 2020-05-21 | — | — | US | disclosed |
| US-20040229038-A1 | Nanoparticulate meloxicam formulations | ELAN PHARMA INTERNATIONAL LTD. | 2004-11-18 | — | — | US | disclosed |
| US-20040173696-A1 | Milling microgram quantities of nanoparticulate candidate compounds | ELAN PHARMA INTERNATIONAL LTD. | 2004-09-09 | — | — | US | disclosed |
| US-20040156872-A1 | Novel nimesulide compositions | ELAN PHARMA INTERNATIONAL LTD. | 2004-08-12 | — | — | US | disclosed |
| WO-2004058216-A2 | MILLING MICROGRAM QUANTITIES OF NANOPARTICULATE CANDIDATE COMPOUNDS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-07-15 | — | — | WO | disclosed |
| US-20040043992-A1 | Meloxicam for alleviating organ injury during organ operation or transplantation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-03-04 | — | — | US | disclosed |
| WO-2003097066-A1 | USE OF MELOXICAM FOR ALLEVIATING ORGAN INJURY DURING ORGAN OPERATION OR TRANSPLANTATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-11-27 | — | — | WO | disclosed |
| EP-0273369-B1 | NEW ALKANESULFONANILIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-04 | — | — | EP | disclosed |
| US-4866091-A | ANTINFLAMMATORY AGENTS, ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-12 | — | — | US | disclosed |
| JP-S63190869-A | NOVEL ALKANESULFONANILIDE DERIVATIVE, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION CONTAINING SAID DERIVATIVE | FUJISAWA PHARMACEUT CO LTD | 1988-08-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156872-A1 | Novel nimesulide compositions | NIM1K, NIT2, NCL | PTGS2 2387/4885BRD4 4717/4885CYP1A2 3009/4885 |
| US-20200155564-A1 | Nanoparticulate Meloxicam Formulations | MTNR1A, MB, MTDH | PTGS2 13/4885BRD4 4103/4885CYP1A2 377/4885 |
| US-10709713-B2 | Nanoparticulate meloxicam formulations | MTNR1A, MB, MTDH | PTGS2 13/4885BRD4 4103/4885CYP1A2 377/4885 |
| US-20210113580-A1 | NANOPARTICULATE MELOXICAM FORMULATIONS | MTNR1A, MB, MTDH | PTGS2 13/4885BRD4 4103/4885CYP1A2 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.